Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Sovleplenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Announces NDA Acceptance In China With Priority Review
    HUTCHMED Announces NDA Acceptance In China With Priority Review

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283539/0/en/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-and-breakthrough-designation-for-sovleplenib-for-the-treatment-of-warm-antibody-autoimmune-hemolytic-anemia.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Hutchmed Heats Up Autoimmune Race With Phase 3 Win
    Hutchmed Heats Up Autoimmune Race With Phase 3 Win

    07 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/hutchmed-heats-autoimmune-race-phase-3-win-teeing-china-filing

    FIERCE BIOTECH
    07 Jan 2026
    Share Share
    HUTCHMED Reports Positive Phase III Data for Sovleplenib in AIHA
    HUTCHMED Reports Positive Phase III Data for Sovleplenib in AIHA

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214208/0/en/HUTCHMED-Announces-Positive-Topline-Results-of-Phase-III-Part-of-ESLIM-02-Trial-of-Sovleplenib-for-Warm-Antibody-Autoimmune-Hemolytic-Anemia-in-China.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024

    16 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/17/2883983/0/en/HUTCHMED-Highlights-Sovleplenib-Phase-III-ESLIM-01-Study-and-Hematological-Malignancy-Programs-Data-to-be-Presented-at-the-upcoming-EHA2024-Congress.html

    GLOBENEWSWIRE
    16 May 2024
    Share Share
    Hutchmed Announces NDA Acceptance in China for Sovleplenib
    Hutchmed Announces NDA Acceptance in China for Sovleplenib

    10 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/11/2807571/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Sovleplenib-for-the-Treatment-of-Primary-Immune-Thrombocytopenia-with-Priority-Review-Status.html

    GLOBENEWSWIRE
    10 Jan 2024
    Share Share
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

    24 Aug 2023

    // ONCLIVE

    https://www.onclive.com/view/sovleplenib-elicits-durable-responses-in-primary-immune-thrombocytopenia

    ONCLIVE
    24 Aug 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.